AU2016202591B2 — An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Assigned to Genzyme Corp · Expires 2017-11-30 · 8y expired
What this patent protects
H:Vc\Intrwovn\NRPortbl\DCC\REC\l0029214_I.docx-21/04/2016 The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the For…
USPTO Abstract
H:Vc\Intrwovn\NRPortbl\DCC\REC\l0029214_I.docx-21/04/2016 The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.